Secretome Therapeutics focuses on developing innovative therapies derived from neonatal cardiac progenitor cells (nCPCs) to address severe cardiovascular and inflammatory diseases. The company leverages the unique biological properties of nCPCs to create therapies aimed at reducing inflammation, preventing fibrosis, and promoting tissue repair. Their lead candidate, STM-01, is currently in Phase 1 clinical trials, indicating a commitment to advancing first-in-class treatments that target critical unmet medical needs.

The company's scientific platform is built on the premise of harnessing the regenerative potential of nCPCs, which are known for their ability to support heart tissue repair and modulate inflammatory responses. With secured patents and ongoing clinical trials, Secretome Therapeutics is positioned to make significant contributions to the field of regenerative medicine, with the ultimate goal of improving patient outcomes for those suffering from complex diseases.

United States

Revolutionizing cell therapy to address inflammatory diseases driven via neonatal cardiac progenitor cells and their secretomes.

Secretome Therapeutics

Company Details